Gilead’s Trodelvy, a breast cancer medicine, makes a comeback as it wins FDA priority review on the application for highly pretreated HR-positive, HER2-negative breast cancer. According to Gilead, the regulatory victory establishes an approval action date of February 2023. Gilead’s Trodelvy application makes use of information from the carefully monitored TROPiCs-02 research, which the firm states fulfiled both of its major endpoints of progression-free survival and overall survival vs. a doctor-selected treatment.
Read More from FiercePharma
English